Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22604
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWilliams, David S-
dc.contributor.authorMouradov, Dmitri-
dc.contributor.authorNewman, Marsali R-
dc.contributor.authorAmini, Elham-
dc.contributor.authorNickless, David K-
dc.contributor.authorFang, Catherine G-
dc.contributor.authorPalmieri, Michelle-
dc.contributor.authorSakthianandeswaren, Anuratha-
dc.contributor.authorLi, Shan-
dc.contributor.authorWard, Robyn L-
dc.contributor.authorHawkins, Nicholas J-
dc.contributor.authorSkinner, Iain-
dc.contributor.authorJones, Ian-
dc.contributor.authorGibbs, Peter-
dc.contributor.authorSieber, Oliver M-
dc.date2020-02-11-
dc.date.accessioned2020-02-18T22:28:57Z-
dc.date.available2020-02-18T22:28:57Z-
dc.date.issued2020-07-
dc.identifier.citationModern Pathology 2020; 33(7): 1420-1432-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/22604-
dc.description.abstractMucinous colorectal adenocarcinoma (CRC) is conventionally defined by extracellular mucin comprising >50% of the tumour area, while tumours with ≤50% mucin are designated as having a mucinous component. However, these definitions are largely arbitrary and comparisons of clinico-molecular features and outcomes by proportion of mucinous component are limited. A cohort of 1643 patients with stage II/III cancer was examined for tumour mucinous component, DNA mismatch repair (MMR) status, BRAF mutation and tumour infiltrating lymphocytes (TILs). Tumours with ≤50% mucinous component exhibited similar characteristics as mucinous tumours, including association with female gender, proximal location, high grade, TIL-high, defective MMR (dMMR) and BRAF mutation. Proportion of mucinous component did not stratify disease-free survival (DFS). In univariate analysis dMMR status, but not histological grade, stratified survival for mucinous and mucinous component tumours; however, in multivariate analysis dMMR status was not an independent predictor. BRAF mutation prognostic value depended on mucinous differentiation and MMR status, with poor prognosis limited to non-mucinous pMMR tumours (HR 2.61, 95% CI 1.69-4.03; p < 0.001). TIL status was a strong independent predictor of DFS in mucinous/mucinous component tumours (HR 0.40, 95% CI 0.23-0.67; p < 0.001), and a superior predictor of prognosis compared with histological grade, MMR and BRAF mutation. Mucinous component and mucinous stage II/III CRCs exhibit clinico-molecular resemblances, with histological grade and BRAF mutation lacking prognostic value. Prognosis for these tumours was instead strongly associated with TIL status, with the most favourable outcomes in TIL-high dMMR tumours, whilst TIL-low tumours had poor outcomes irrespective of MMR status.-
dc.language.isoeng-
dc.titleTumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation.-
dc.typeJournal Article-
dc.identifier.journaltitleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc-
dc.identifier.affiliationClinipath Pathology, Sonic Healthcare, Perth, WA, Australiaen
dc.identifier.affiliationDepartment of Surgery, Royal Melbourne Hospital, Parkville, VIC, Australiaen
dc.identifier.affiliationDepartment of Surgery, Western Health, Footscray, VIC, Australiaen
dc.identifier.affiliationMelbourne Pathology, Cabrini Health, Malvern, VIC, Australiaen
dc.identifier.affiliationDepartment of Pathology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Clinical Pathology, The University of Melbourne, Parkville, VIC, Australiaen
dc.identifier.affiliationPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australiaen
dc.identifier.affiliationDepartment of Medical Biology, The University of Melbourne, Parkville, VIC, Australiaen
dc.identifier.affiliationPrince of Wales Clinical School and Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, Australiaen
dc.identifier.affiliationFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australiaen
dc.identifier.affiliationSchool of Medical Sciences, UNSW Sydney, Sydney, NSW, Australiaen
dc.identifier.affiliationFaculty of Medicine, The University of Queensland, Herston, QLD, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Parkville, VIC, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Western Health, Footscray, VIC, Australiaen
dc.identifier.affiliationDepartment of Surgery, The University of Melbourne, Parkville, VIC, Australiaen
dc.identifier.affiliationSchool of Biomedical Sciences, Monash University, Clayton, VIC, Australiaen
dc.identifier.doi10.1038/s41379-020-0496-1-
dc.identifier.orcid0000-0001-9480-0786-
dc.identifier.pubmedid32047231-
dc.type.austinJournal Article-
local.name.researcherNewman, Marsali R
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptPathology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

28
checked on Nov 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.